Advertisement
ALGN vs NVST
Which Stock Would AI Choose? Align Technology (ALGN) vs. Envista Holdings (NVST) Stock Comparison
Key Takeaways
- Both ALGN and NVST have delivered strong year-to-date (YTD) gains of approximately 22-23% in recent market activity, reflecting resilience in the dental sector.
- NVST has significantly outperformed ALGN over the past year with a 68% return compared to 4%, driven by post-earnings momentum.
- ALGN trades at a more attractive trailing price-to-earnings (P/E) ratio of around 34 versus NVST's 96, suggesting better current valuation relative to earnings.
- Upcoming quarterly earnings for both companies could influence near-term sentiment, with ALGN guiding modest 2026 revenue growth of 3-4% and NVST targeting 2-4% core sales growth.
- ALGN boasts a larger market cap of $13.7 billion compared to NVST's $4.4 billion, offering greater scale but higher beta (1.81 vs. 0.99).
- Investor interest remains elevated in dental stocks amid steady demand for orthodontic and equipment solutions.
Introduction
This stock comparison examines ALGN and NVST, two key players in the dental and medical devices sector. Both companies benefit from enduring demand for orthodontic treatments and dental consumables, making them relevant for growth-oriented investors and traders monitoring healthcare subsectors. Recent market activity has highlighted their relative performance amid broader economic shifts, providing insights into valuation, momentum, and sector positioning. Traders seeking exposure to dental innovation may find value in understanding their contrasts in scale, growth trajectories, and risk profiles.
ALGN Overview and Recent Performance
Align Technology (ALGN), the maker of Invisalign clear aligners and iTero intraoral scanners, dominates the digital orthodontics market. In recent weeks, ALGN shares have rebounded toward their 52-week high near $208, trading around $191 with a market cap of $13.7 billion. Year-to-date gains stand at 22%, supported by Q4 2025 results that beat estimates, including record revenue and EPS of $3.29. Management guided 2026 Clear Aligner volume growth in mid-single digits and overall revenue up 3-4%, fueled by direct-to-consumer adoption and international expansion. Sentiment has improved on innovation awards and pre-earnings optimism for Q1 2026, though higher beta reflects sensitivity to market swings.
NVST Overview and Recent Performance
Envista Holdings (NVST) provides a broad portfolio of dental products, including implants, orthodontics, and imaging equipment under brands like Nobel Biocare and Kerr. Shares have climbed to about $27, with a $4.4 billion market cap, posting YTD returns of 23% and a robust 68% over the past year. Recent strength followed Q4 beats, with EPS of $0.38 and 15% quarterly revenue growth, prompting 2026 guidance of 2-4% core sales and adjusted EPS of $1.35-$1.45. Product launches like ZenSeal and Demi Pro have bolstered operational momentum, while a lower beta of 0.99 indicates relative stability. Pre-Q1 earnings positioning has sustained positive trader interest.
Trending AI Robots
Tickeron’s Trending AI Robots page features a curated selection of 25 top-performing AI trading bots from over 350 available, each scanning thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies—such as pattern recognition, momentum trading, and fundamental analysis—with timeframes from 5 minutes to 60 days, win rates typically ranging 55-70%, profit factors of 1.5-4.5, and annualized returns often exceeding 50-100% for leaders like semiconductor-focused agents. Virtual and brokerage agents incorporate risk management, including take-profit/stop-loss corridors. Ideal for current volatile conditions, they adapt to sectors like technology and industrials. Explore these high-conviction signals to enhance your trading edge.
Head-to-Head Comparison
ALGN and NVST operate in overlapping dental markets but diverge in focus: ALGN specializes in disruptive clear aligner systems, driving growth via volume and digital scanning, while NVST emphasizes diversified consumables and equipment for broader implant/ortho needs. Recent momentum favors NVST with superior one-year returns, though ALGN offers scale advantages and tighter valuation on trailing P/E. Risk profiles differ, with ALGN’s higher beta exposing it to volatility versus NVST’s steadier profile. Sector exposure is similar, but NVST shows stronger quarterly growth trades-offs amid product innovation.
Tickeron AI Verdict
Tickeron’s AI models currently lean toward NVST based on stronger relative momentum, impressive one-year outperformance, and aligned growth guidance in recent market conditions. While ALGN exhibits solid stability and upcoming catalysts, NVST’s positioning suggests higher probability of continued upside in the near term, subject to earnings outcomes and sector trends.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALGN is a Hold and NVST is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALGN’s FA Score shows that 0 FA rating(s) are green whileNVST’s FA Score has 0 green FA rating(s).
- ALGN’s FA Score: 0 green, 5 red.
- NVST’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALGN’s TA Score shows that 4 TA indicator(s) are bullish while NVST’s TA Score has 4 bullish TA indicator(s).
- ALGN’s TA Score: 4 bullish, 6 bearish.
- NVST’s TA Score: 4 bullish, 5 bearish.
Price Growth
ALGN (@Pharmaceuticals: Other) experienced а +4.23% price change this week, while NVST (@Pharmaceuticals: Other) price change was +6.49% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.49%. For the same industry, the average monthly price growth was +1.13%, and the average quarterly price growth was -15.35%.
Reported Earning Dates
ALGN is expected to report earnings on Jul 29, 2026.
NVST is expected to report earnings on Aug 05, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-0.49% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| ALGN | NVST | ALGN / NVST | |
| Capitalization | 12.5B | 4B | 312% |
| EBITDA | 877M | 388M | 226% |
| Gain YTD | 11.969 | 13.312 | 90% |
| P/E Ratio | 29.38 | 60.00 | 49% |
| Revenue | 4.1B | 2.81B | 146% |
| Total Cash | 1.06B | 1.08B | 98% |
| Total Debt | 116M | 1.59B | 7% |
ALGN | NVST | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 6 | 6 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 70 Overvalued | 72 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 69 | 90 | |
PRICE GROWTH RATING 1..100 | 49 | 49 | |
P/E GROWTH RATING 1..100 | 64 | 59 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ALGN's Valuation (70) in the Medical Specialties industry is in the same range as NVST (72) in the null industry. This means that ALGN’s stock grew similarly to NVST’s over the last 12 months.
ALGN's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as NVST (100) in the null industry. This means that ALGN’s stock grew similarly to NVST’s over the last 12 months.
ALGN's SMR Rating (69) in the Medical Specialties industry is in the same range as NVST (90) in the null industry. This means that ALGN’s stock grew similarly to NVST’s over the last 12 months.
ALGN's Price Growth Rating (49) in the Medical Specialties industry is in the same range as NVST (49) in the null industry. This means that ALGN’s stock grew similarly to NVST’s over the last 12 months.
NVST's P/E Growth Rating (59) in the null industry is in the same range as ALGN (64) in the Medical Specialties industry. This means that NVST’s stock grew similarly to ALGN’s over the last 12 months.
| ALGN | NVST | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 69% | 3 days ago 69% |
| Stochastic ODDS (%) | 3 days ago 69% | 3 days ago 79% |
| Momentum ODDS (%) | 3 days ago 70% | 3 days ago 67% |
| MACD ODDS (%) | 3 days ago 56% | 3 days ago 63% |
| TrendWeek ODDS (%) | 3 days ago 73% | 3 days ago 64% |
| TrendMonth ODDS (%) | 3 days ago 69% | 3 days ago 66% |
| Advances ODDS (%) | 6 days ago 71% | 3 days ago 63% |
| Declines ODDS (%) | 12 days ago 74% | 12 days ago 71% |
| BollingerBands ODDS (%) | 3 days ago 77% | 3 days ago 81% |
| Aroon ODDS (%) | 3 days ago 71% | 3 days ago 76% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| EIPX | 32.08 | 0.25 | +0.79% |
| FT Energy Income Partners Strategy ETF | |||
| QGRD | 29.93 | 0.15 | +0.52% |
| Horizon NASDAQ-100 Defined Risk ETF | |||
| VCR | 392.77 | 0.78 | +0.20% |
| Vanguard Consumer Discretionary ETF | |||
| BTRN | 25.17 | N/A | N/A |
| Global X Bitcoin Trend Strategy ETF | |||
| MGOV | 20.15 | -0.06 | -0.30% |
| First Trust Intermediate Gvt Opps ETF | |||
NVST and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVST has been loosely correlated with XRAY. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if NVST jumps, then XRAY could also see price increases.
| Ticker / NAME | Correlation To NVST | 1D Price Change % | ||
|---|---|---|---|---|
| NVST | 100% | +0.41% | ||
| XRAY - NVST | 63% Loosely correlated | -0.49% | ||
| ALGN - NVST | 57% Loosely correlated | -0.95% | ||
| BIO - NVST | 57% Loosely correlated | -2.22% | ||
| A - NVST | 55% Loosely correlated | +0.22% | ||
| MTD - NVST | 52% Loosely correlated | -0.86% | ||
More | ||||